Title: Thiocarbamate Inhibitors of Insulin-Degrading Enzyme
Case Number: 2011-047
Innovators: Malcolm A. Leissring Ph.D.; Samer Abdul-Hay Ph.D.; Clemence Claussin
Description
IDE inhibitors for the treatment of diabetes
Technology Description
Current therapeutic strategies for managing diabetes include increasing insulin levels by direct injection, stimulating insulin production, and improving insulin effectiveness. Modulating insulin degrading enzyme (IDE) activity represents another potential means by which insulin levels may be increased. IDE is the principle enzyme responsible for the degradation of insulin and is expressed ubiquitously. Although IDE has been studied for more than 60 years, the discovery of IDE inhibitors has been hampered by the unique conformation of the enzyme active site. Mayo Clinic researchers have developed unique and sensitive assay methodologies to facilitate compound library screening for IDE inhibitors. Multiple classes of small molecule compounds have been identified that inhibit IDE activity. Studies using some of the IDE inhibitors demonstrated favorable regulation of insulin catabolism and signaling, consistent with therapeutic utility for diabetes.
Application
IDE inhibitors could potentially be used to increase circulating insulin levels and potentiate insulin signaling for the treatment of diabetes.
Stage of Development
Multiple classes of small molecule inhibitors have been identified and additional characterization and structure-activity relationship (SAR) studies are ongoing.
Patent Status: Provisional
Licensing Contact
Manu S. Nair, 507-266-0558
nair.manu@mayo.edu
Categories
Technology Category/Therapeutic
Technology Category/Research Tool-Method
Keywords
Metabolic Disease
|
|
| |
| Name |
Description |
Open Link |
|---|
|
|
|
|
Licensing opportunities »who we are » contact us » News » 
